原发不可切除或复发转移性胃肠间质瘤的治疗现状

李 金金, 黄 镇, 周 辉, 张 军*

参考

[1]Blay,J.Y.,etal.,Gastrointestinalstromaltumours.NatRevDisPrimers,2021.7(1):p.22.[2]Quek,R.andS.George,Gastrointestinalstromaltumor:aclinicaloverview.HematolOncolClinNorthAm,2009.23(1):p.69-78,viii.[3]Corless,C.L.,C.M.Barnett,andM.C.Heinrich,Gastrointestinalstromaltumours:originandmolecularoncology.NatRevCancer,2011.11(12):p.865-78.[4]Demetri,G.D.,etal.,Efficacyandsafetyofimatinibmesylateinadvancedgastrointestinalstromaltumors.NEnglJMed,2002.347(7):p.472-80.[5]DeMatteo,R.P.,etal.,Twohundredgastrointestinalstromaltumors:recurrencepatternsandprognosticfactorsforsurvival.AnnSurg,2000.231(1):p.51-8.[6]Casali,P.G.,etal.,Ten-YearProgression-FreeandOverallSurvivalinPatientsWithUnresectableorMetastaticGIStromalTumors:Long-TermAnalysisoftheEuropeanOrganisationforResearchandTreatmentofCancer,ItalianSarcomaGroup,andAustralasianGastrointestinalTrialsGroupIntergroupPhaseIIIRandomizedTrialonImatinibatTwoDoseLevels.JClinOncol,2017.35(15):p.1713-1720.[7]Heinrich,M.C.,etal.,Primaryandsecondarykinasegenotypescorrelatewiththebiologicalandclinicalactivityofsunitinibinimatinib-resistantgastrointestinalstromaltumor.JClinOncol,2008.26(33):p.5352-9.[8]Demetri,G.D.,etal.,Moleculartargetmodulation,imaging,andclinicalevaluationofgastrointestinalstromaltumorpatientstreatedwithsunitinibmalateafterimatinibfailure.ClinCancerRes,2009.15(18):p.5902-9.[9]Demetri,G.D.,etal.,Efficacyandsafetyofsunitinibinpatientswithadvancedgastrointestinalstromaltumourafterfailureofimatinib:arandomisedcontrolledtrial.Lancet,2006.368(9544):p.1329-38.[10]Demetri,G.D.,etal.,Efficacyandsafetyofregorafenibforadvancedgastrointestinalstromaltumoursafterfailureofimatinibandsunitinib(GRID):aninternational,multicentre,randomised,placebo-controlled,phase3trial.Lancet,2013.381(9863):p.295-302.[11]Smith,B.D.,etal.,Ripretinib(DCC-2618)IsaSwitchControlKinaseInhibitorofaBroadSpectrumofOncogenicandDrug-ResistantKITandPDGFRAVariants.CancerCell,2019.35(5):p.738-751.e9.[12]Li,J.,etal.,Efficacyandsafetyofripretinibvs.sunitinibinpatientswithadvancedgastrointestinalstromaltumorpreviouslytreatedwithimatinib:Aphase2,multicenter,randomized,open-labelstudyinChina.EurJCancer,2024.196:p.113439.[13]Heinrich,M.C.,etal.,AvapritinibinadvancedPDGFRAD842V-mutantgastrointestinalstromaltumour(NAVIGATOR):amulticentre,open-label,phase1trial.LancetOncol,2020.21(7):p.935-946.[14]Cai,Z.,etal.,Roleofsurgicalresectionforpatientswithrecurrentormetastaticgastrointestinalstromaltumors:Asystematicreviewandmeta-analysis.IntJSurg,2018.56:p.108-114.[15]Mussi,C.,etal.,Post-imatinibsurgeryinadvanced/metastaticGIST:isitworthwhileinallpatients?AnnOncol,2010.21(2):p.403-408.[16]Fairweather,M.,etal.,CytoreductiveSurgeryforMetastaticGastrointestinalStromalTumorsTreatedWithTyrosineKinaseInhibitors:A2-institutionalAnalysis.AnnSurg,2018.268(2):p.296-302.[17]Jung,J.H.,etal.,SafetyandEfficacyofRadiofrequencyAblationforHepaticMetastasesfromGastrointestinalStromalTumor.JVascIntervRadiol,2015.26(12):p.1797-1802.[18]Jones,R.L.,etal.,Radiofrequencyablationisafeasibletherapeuticoptioninthemultimodalitymanagementofsarcoma.EurJSurgOncol,2010.36(5):p.477-82.[19]Yamanaka,T.,etal.,Radiofrequencyablationforlivermetastasisfromgastrointestinalstromaltumor.JVascIntervRadiol,2013.24(3):p.341-6.[20]Hakimé,A.,etal.,AroleforadjuvantRFAinmanaginghepaticmetastasesfromgastrointestinalstromaltumors(GIST)aftertreatmentwithtargetedsystemictherapyusingkinaseinhibitors.CardiovascInterventRadiol,2014.37(1):p.132-9.[21]Takaki,H.,etal.,Hepaticarteryembolizationforlivermetastasisofgastrointestinalstromaltumorfollowingimatinibandsunitinibtherapy.JGastrointestCancer,2014.45(4):p.494-9.[22]Kobayashi,K.,etal.,Hepaticarterychemoembolizationfor110gastrointestinalstromaltumors:response,survival,andprognosticfactors.Cancer,2006.107(12):p.2833-41.[23]Zhang,H.,etal.,RadiotherapyintheManagementofGastrointestinalStromalTumors:ASystematicReview.Cancers(Basel),2022.14(13).